Candel Therapeutics (CADL) Enterprise Value (2020 - 2025)
Candel Therapeutics (CADL) posted Enterprise Value of -$119.7 million for Q4 2025, down 37.68% sequentially from -$87.0 million in Q3 2025, and down 16.64% YoY from -$143.6 million in Q4 2024.
Candel Therapeutics (CADL) Enterprise Value (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Enterprise Value for 6 years, with the latest figure at -$119.7 million in Q4 2025.
- Quarterly Enterprise Value fell 16.64% year-over-year to -$119.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$119.7 million (down 16.64% YoY) and the FY2025 annual result came in at -$119.7 million, down 16.64% from the prior year.
- Enterprise Value retreated to -$119.7 million in Q4 2025 per CADL's latest filing, from -$87.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$16.6 million in Q3 2024 and troughed at -$119.7 million in Q4 2025.
- A 5-year average of -$67.3 million and a median of -$77.2 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 61.49% in 2024, then slumped 425.2% in 2025.
- Over 5 years, Enterprise Value stood at -$82.6 million in 2021, then grew by 15.23% to -$70.1 million in 2022, then soared by 49.45% to -$35.4 million in 2023, then plunged by 189.88% to -$102.7 million in 2024, then declined by 16.64% to -$119.7 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$119.7 million, -$87.0 million, and -$100.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -119.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -119.73 Mn |
| Sep 30, 2025 | -86.96 Mn |
| Jun 30, 2025 | -100.69 Mn |
| Mar 31, 2025 | -92.17 Mn |
| Dec 31, 2024 | -102.65 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Jun 30, 2024 | -21.45 Mn |
| Mar 31, 2024 | -25.71 Mn |
| Dec 31, 2023 | -35.41 Mn |
| Sep 30, 2023 | -43.00 Mn |
| Jun 30, 2023 | -51.90 Mn |
| Mar 31, 2023 | -59.26 Mn |
| Dec 31, 2022 | -70.06 Mn |
| Sep 30, 2022 | -77.18 Mn |
| Jun 30, 2022 | -86.78 Mn |
| Mar 31, 2022 | -94.32 Mn |
| Dec 31, 2021 | -82.64 Mn |
| Sep 30, 2021 | -88.39 Mn |
| Jun 30, 2021 | -24.32 Mn |
| Dec 31, 2020 | -35.05 Mn |